Ozarelix

N/A

Report date: 2024/01/16 10:44:01
NME

Base Information

Drug NameOzarelix
Drug Alias Name奥扎瑞克OzarelixumD-63153SPI-153
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGonadotropin-releasing hormone antagonists
TargetsGonadotropin-releasing hormone
Therapy Area/IndicationsLower Urinary Tract SymptomsProstatic HyperplasiaProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCOSCIENS Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSpectrum Pharmaceuticals IncNippon Kayaku Co Ltd
Active IndicationsN/A
Inactive IndicationsLower Urinary Tract SymptomsProstatic HyperplasiaProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A